Balyasny Asset Management
DNTH icon

Balyasny Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Balyasny Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Sell
162,005
-312,080
-66% -$27.3M 0.02% 834
2026
Q1 		$39.8M Buy
+474,085
New +$27.5M 0.05% 419
2025
Q4 		– Sell
-443,703
Closed -$17.5M – 3191
2025
Q3 		$17.5M Buy
+443,703
New +$11.3M 0.02% 776
2024
Q2 		– Sell
-13,371
Closed -$401K – 2683
2024
Q1 		$401K Buy
+13,371
New +$291K ﹤0.01% 2140
2022
Q4 		– Sell
-761
Closed -$17K – 2875
2022
Q3 		$17K Buy
+761
New +$20.8K ﹤0.01% 2596

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Balyasny Asset Management's DNTH Position: Q2 2026 in Review

Balyasny Asset Management reduced its Dianthus Therapeutics (DNTH) stake by 66% in Q2 2026, selling an estimated $27.3M and leaving 162,005 shares worth $15.8M. The position accounts for 0.02% of the portfolio, ranked #834.

Balyasny Asset Management first reported a position in DNTH in Q3 2022 and has held it in 5 quarters since. The position peaked at $39.8M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Balyasny Asset Management held 162,005 shares of Dianthus Therapeutics worth $15.8M as of Q2 2026.
  • Balyasny Asset Management sold 312,080 Dianthus Therapeutics shares in Q2 2026, an estimated $27.3M.
  • Dianthus Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #834 holding.
  • Balyasny Asset Management first reported a position in Dianthus Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • Balyasny Asset Management's Dianthus Therapeutics position peaked at $39.8M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.